Dec 12, 2025 07:00AM Castle Biosciences test shows improved cancer risk prediction

Nov 14, 2025 07:01AM Castle Biosciences presents melanoma test data at European congress

Nov 4, 2025 03:59PM Castle Biosciences (CSTL) PT Raised to $38 at BTIG

Nov 4, 2025 03:20AM Canaccord Genuity Reiterates Buy Rating on Castle Biosciences (CSTL)

Nov 3, 2025 04:26PM Castle Biosciences Inc. (CSTL) Tops Q3 EPS by 50c

Nov 3, 2025 07:02AM Conexeu Sciences appoints Miles Harrison as CEO

Nov 3, 2025 07:00AM Conexeu Sciences Appoints Miles Harrison as President & Chief Executive Officer, to Shape the Future of True Tissue Regeneration

Oct 27, 2025 12:27AM Castle Biosciences presents TissueCypher test data at gastroenterology meeting

Aug 25, 2025 07:01AM Castle Biosciences publishes studies supporting cancer test use

Aug 4, 2025 04:23PM Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 66c

Jul 23, 2025 07:01AM Castle Biosciences receives FDA breakthrough designation for melanoma test

Jun 17, 2025 07:06AM Canaccord Genuity Reiterates Buy Rating on Castle Biosciences (CSTL)

Jun 16, 2025 04:31PM Castle Biosciences Inc. (CSTL) Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

May 21, 2025 12:40PM Castle Biosciences (CSTL) PT Lowered to $40 at Scotiabank

May 9, 2025 07:01AM Castle Biosciences Inc. (CSTL) announces new data from the first independent validation of the recently published Collaborative Ocular Oncology Group

May 6, 2025 08:22AM KeyBanc Reiterates Overweight Rating on Castle Biosciences (CSTL) as 'TissueCypher Gains Momentum'

May 6, 2025 06:41AM Castle Biosciences (CSTL) PT Lowered to $32 at BTIG

May 5, 2025 04:45PM Castle Biosciences Inc. (CSTL) Misses Q1 EPS by 14c

May 5, 2025 04:05PM Castle Biosciences Inc. (CSTL) to Acquire Previse

Apr 8, 2025 07:02AM Castle Biosciences (CSTL) Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Feb 27, 2025 04:14PM Castle Biosciences Inc. (CSTL) Tops Q4 EPS by 31c, provides guidance

Jan 10, 2025 02:38PM Castle Biosciences Inc. (CSTL) Weakness Tied to Adverse Coverage Determination

Jan 6, 2025 07:03AM Castle Biosciences (CSTL) Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test

Dec 23, 2024 07:05AM Castle Biosciences (CSTL) Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test

Dec 19, 2024 06:56AM Canaccord Genuity Reiterates Buy Rating on Castle Biosciences (CSTL), 'remain highly bullish'

Nov 5, 2024 03:50PM Castle Biosciences (CSTL) PT Raised to $45 at BTIG

Nov 5, 2024 11:49AM Castle Biosciences (CSTL) PT Raised to $36 at KeyBanc

Nov 5, 2024 06:54AM Castle Biosciences (CSTL) PT Raised to $39 at Baird

Nov 5, 2024 06:14AM Canaccord Genuity Reiterates Buy Rating on Castle Biosciences (CSTL)

Nov 4, 2024 04:21PM Castle Biosciences Inc. (CSTL) Tops Q3 EPS by 8c, provides guidance

Oct 29, 2024 06:30AM Castle Biosciences (CSTL) PT Raised to $42 at Canaccord Genuity

Oct 14, 2024 06:47AM Castle Biosciences (CSTL) PT Raised to $40 at BTIG

Aug 6, 2024 07:31AM Castle Biosciences (CSTL) PT Raised to $35 at BTIG

Aug 6, 2024 06:52AM Castle Biosciences (CSTL) PT Raised to $37 at Baird

Aug 5, 2024 04:20PM Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 58c, Beats on Revenue; Offers FY24 Revenue Guidance